SYNGENE384.00

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹15,471 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity11.9810.506.546.54
Return on Assets8.297.304.494.49
Return on Capital Employed11.7511.288.468.46
Return on Invested Capital12.7211.848.626.38
Margins
EBITDA Margin29.0828.6024.5722.30
Operating Margin16.8716.7312.4512.45
Incremental Operating Margin13.46-149.12
Pretax Margin17.8018.1210.998.07
Net Income Margin14.6213.628.476.14
FCF Margin15.2310.9114.6314.63
Additional
Effective Tax Rate17.8524.8122.9323.90
Dvd Payout Ratio9.8610.1415.91
Sustainable Growth Rate10.809.445.506.54
Incremental Operating Margin %13.46-149.1284.19
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.